Business briefs: GSK, DOJ, Sanofi, Flashpoint Medica

Share this article:

GlaxoSmithKline dismissed its SVP and head of R&D in Shanghai, Jingwu Zang, over fabricated data which was published in the scientific journal Nature. GSK has also placed three other employees on administrative leave pending a final review, and one other employee has resigned as a result of the allegations. The three-year-old paper in question examined the role of a protein called Interleukin-7 in treating autoimmune disorders.

The Justice Department agreed to stop trying to block the availability of over-the-counter Plan-B today. The New York Times reported that the Justice Department “appears to have concluded that it might its case with the appeals court and would have to decide whether to appeal to the Supreme Court,” an unlikely move which would cast the delicate issue and it's back-and-forth into the political limelight.

FDA approved Sanofi's Fluzone Quadrivalent. The new flu vaccine protects against four strains of the disease and is approved for use in children six months of age and older along with adolescents and adults. Fluzone Quadrivalent will see its first flu season in 2013.

Flashpoint Medica chief Charlene Prounis was selected by the Women's Venture Fund to receive the “Highest Leaf Award.” The annual award is given to women executives “who contribute significantly to their respective industries while assisting other women in developing the skills and resources for attaining their own business goals.”  The Highest Leaf Award will be presented to Prounis, who is CEO and managing partner of Flashpoint Medica, on Wednesday, June 12 at the Harvard Club in New York City.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.